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The treatment of agitation and aggression, typical Behavioural and Psychological Symptoms of Dementia (BPSDs) of Alzheimer’s
Disease (AD), is one of the most complicated aspects of handling patients suffering from dementia. Currently, the management of
these symptoms often associated with an increased pain perception, which notably reduces the patients’ quality of life (QoL), relies
on the employment of antipsychotic drugs. Unfortunately, the use of these pharmacological agents has some limits: in the long term,
they do not result in being equally effective as in the first weeks of treatment and they present important side effects. Therefore,
there is growing interest, supported by clinical evidence, in aromatherapy for the control of agitation, aggression, and psychotic
symptoms. Some molecular mechanisms have been proposed to explain the behavioural effects of essential oils, as the whole
phytocomplex or the single components, but important basic research effort is still needed. For this reason, rigorous preclinical
studies are necessary in order to understand the pharmacological basis of aromatherapy in the treatment of BPSDs and to widen
the cluster of effective essential oils in pharmacotherapeutic practice.
1. Introduction: Characterization of
Alzheimer’s Disease
Alzheimer’s Disease (AD), originally described by Alzheimer
in 1907 [1], is the most common cause of dementia in the
elderly: 35 million people all over the world are affected
by dementia [2] and, according to the survey made by the
World Health Organization (WHO) in 2012, 54% of all the
cases of dementia are AD-related. These data account for the
social burden of ADworldwide. Other forms of dementia are
Lewy body dementia, frontotemporal dementia, and vascular
dementia. AD is a progressive neurodegenerative disease
characterized by cognitive and noncognitive dysfunctions
[3]. In particular, the WHO describes dementia as a clinical
syndrome due to disease of the brain, usually of a progres-
sive nature, which leads to disturbances of multiple higher
cortical functions, including memory, thinking, orientation,
comprehension, calculation, learning capacity, language, and
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judgment. The cognitive deficits include memory impair-
ment, aphasia, apraxia, agnosia, and disturbances in executive
functioning [4, 5]. Although these are the fundamental goal
in the long term, the most frequent issue for people with AD
remains the management of Behavioural and Psychological
Symptoms of Dementia (BPSDs) [6] and pain [7]. The
pathogenesis of AD is explained by the amyloid hypothesis,
according to which deposition and accumulation of amyloid
𝛽-peptide (A𝛽) are responsible for the neurodegeneration;
thus the reduction of A𝛽 plaques should produce clini-
cal improvement [8]. Other neuropathological markers of
AD are the neurofibrillary tangles (NFTs), composed of
hyperphosphorylated tau proteins. Available drugs for the
pharmacological treatment of AD are acetylcholinesterase
inhibitors: Donepezil (Aricept, 1996), Rivastigmine (Exelon,
1998), and Galantamine (Razadyne, 2001). A more recently
approved drug by Food and Drug Administration (FDA) is
effective in AD-induced cognitive impairment, that is, the
noncompetitive N-methyl-D-aspartate- (NMDA-) receptor
antagonist Memantine (Namenda, 2003). New strategies tar-
geting A𝛽 have been tested in order to delay AD progression,
but small molecules and immunotherapy both have failed
[9]. For this purpose, novel biological drugs have been
studied as disease-modifying agents for AD. In particu-
lar, two placebo-controlled multicenter, double-blind phase
3 studies on mild-to-moderate AD, EXPEDITION 1 and
EXPEDITION 2, unraveled that Solanezumab, a humanized
antiamyloid monoclonal antibody, which binds soluble A𝛽,
did not show significant results concerned with the primary
outcomes, failed to improve cognition, and did not enhance
functional ability (funded by Eli Lilly; EXPEDITION 1 and
EXPEDITION 2 ClinicalTrials.gov numbers NCT00905372
and NCT00904683) [10]. Also Bapineuzumab, a human-
ized anti-amyloid-beta monoclonal antibody, was studied in
two double-blind, randomized, placebo-controlled phase 3
trials on mild-to-moderate AD; the results demonstrated
that Bapineuzumab did not produce any improvements of
the set clinical outcomes (funded by Janssen Alzheimer
Immunotherapy and Pfizer; Bapineuzumab 301 and 302 Clin-
icalTrials.gov numbers NCT00575055 andNCT00574132 and
EudraCT number 2009-012748-17.) [11]. Interestingly, Adu-
canumab (BIIB037), a human monoclonal antibody able to
bind A𝛽 aggregates (soluble and insoluble form), was tested
in a double-blind, placebo-controlled phase 1b randomized
trial (PRIME; ClinicalTrials.gov identifier NCT01677572)
involving patients showing prodromal or mild AD; Adu-
canumab administration resulted in a reduction of brain A𝛽
plaques in a dose- and time-dependent manner, as shown
in Florbetapir PET imaging [12]. Moreover, Aducanumab
trial demonstrated an improvement of the Mini Mental State
Examination (MMSE) at one year, mainly at the doses of
3 and 10mg/Kg and of the Clinical Dementia Rating-Sum
of Boxes (CDR-SB) score at one year [12]. Therefore, the
studies on Aducanumab support the amyloid hypothesis
and demonstrate that the use of Aducanumab could be an
interesting disease-modifying approach for AD treatment in
the still ongoing long-term extension (LTE) phase of the
PRIME and phase 3 studies [12].
2. Strategy for the Management of BPSDs
Dementia is widespread among patients hosts of nursing care
homes, since up to 80% of them suffer from it [13]. Lots of
patients affected by dementia, in particular 40–60% of the
residents in care homes [14], developBPSDs.These symptoms
include agitation, aggression, psychotic manifestations with
consequent stress, increased pain perception, and decreased
quality of life (QoL). In order to establish the most suitable
treatment for each individual condition, a rigorous evaluation
of the symptoms and assessment of pain is necessary; the
latter is made much more complicated in AD patients due
to their difficulty to convey what they perceive. The atypical
antipsychotic drugs have replaced the typical ones in the
treatment of BPSDs because of the improved safety shown in
the treatment of schizophrenic patients; indeed, the atypical
antipsychotics (Risperidone, Olanzapine, Aripiprazole, and
Quetiapine) were developed for schizophrenia therapy [15].
Among these drugs, Risperidone is the safest antipsychotic
drug for short-term therapy of BPSDs in patients with
dementia, even if it needs an accurate review of the treatment
[15]. Furthermore, since chronic pain affects mainly the
population of the elderly, it often accompanies patients
suffering from dementia, determining a reduction of the QoL
almost as remarkable as that provoked by memory loss. Pain
takes on a pivotal importance in demented patients, because
it plays a fundamental role in the development of the BPSDs,
in particular of agitation and aggression [16]. In AD pain
perception is impaired because of neuropathological changes
of the pain systems, in particular in the locus coeruleus [17]
and in the periaqueductal gray [18]. For this reason, the
effect of pain treatment on patients’ agitation has been tested.
During a multicenter cluster randomized controlled trial
(ClinicalTrials.gov NCT01021696 and Norwegian Medicines
Agency EudraCTnr 2008-007490-20) [19], carried out in
Norway from October 2009 to June 2010 in 60 nursing
homes, 65-year-old or older demented patients affected by
BPSDs (apart from the patients belonging to the control
group that were treated as they usually were) received
different analgesic drugs according to a standardized stepwise
protocol: oral paracetamol, oral morphine, buprenorphine
transdermal patch, or oral pregabalin. The primary out-
come was agitation, assessed through the Cohen-Mansfield
agitation inventory, while the secondary outcomes were
aggression, pain, cognition, and daily activities. The results
demonstrated a significant average reduction in agitation
of 17% in the intervention group compared to the control
group; the former presented an increased agitation score
when painkillers were withdrawn [19]. Therefore, this study
supports the importance of an adequate evaluation and treat-
ment of pain for the management of agitation and aggression
in patients suffering from dementia. Indeed, an appropriate
treatment strategy for BPSDs needs a complex evaluation of
the several multiple symptoms manifested by the patients, so
that pharmacological agents are not administered if not or
until necessary.
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3. The Antipsychotics
The typical antipsychotics have been the first off-label phar-
macological treatment of BPSDs. In order to study the effect
of haloperidol in agitated demented patients, a search was
made on databases such as MEDLINE, EMBASE, PsycInfo,
and CINAHL: five randomized, placebo-controlled trials
were included. The results yielded by the completed four
randomized controlled trials (RCTs) have proven evidence
for the effectiveness of haloperidol on aggression, when
compared to placebo, but not on other manifestations of
agitation [20, 21]. The relative effectiveness of these agents
was counterbalanced by their serious side effects especially
about the cardiac sphere and the parkinsonism. Indeed, a
study on 495 psychiatric patients (with 101 healthy controls)
demonstrated that these antipsychotic agents were predictors
of QTc lengthening in a dose-relatedmanner [22].Thus, soon
the novel atypical antipsychotics like Risperidone, Olanzap-
ine, and Quetiapine took the place of the older typical agents
in the management of aggression and agitation in dementia,
thanks to their improved tolerability. Part of the amount
of data collected in placebo-controlled trials on atypical
antipsychotic drugs in AD is not available; at variance with
the latter, all the results generated through meta-analyses on
Risperidone and Aripiprazole are available [21]. In particular,
these drugs result effective in controlling aggressionmainly in
a treatment period of 6–12 weeks, with larger evidence base
for Risperidone [21, 23, 24]. Unfortunately, the randomized
controlled trials lasting for a longer period have not high-
lighted efficacy of atypical antipsychotics in the long-term
and, even when some effectiveness occurred, the incidence
of side effects made it irrelevant in terms of cost/effectiveness
[21, 25, 26]. For instance, a randomized double-blind placebo-
controlled trial, conducted on 93 patients, guests of care
facilities in Newcastle and who are affected by AD or demen-
tia, showed that Quetiapine did not produce significant
improvements in agitation score measured with Cohen-
Mansfield agitation inventory but was associatedwith aworse
decline of cognition assessed by severe impairment battery
at 6 and 26 weeks [25]. Another double-blind placebo-
controlled trial (ClinicalTrials.gov number NCT00015548)
made on AD outpatients evaluated the effects of Olanzapine,
Quetiapine, and Risperidone with respect to placebo [26].
The primary outcome of this trial, which made part of
the National Institute of Mental Health (NIMH) Clinical
Antipsychotic Trials of Intervention Effectiveness, was the
time until discontinuation of treatment for any reason in
phase 1: the median time to discontinuation of treatment
for any reason resulted in being 5–8 weeks, without any sig-
nificant differences among the three atypical antipsychotics
and between them and the placebo [26]. Moreover, the time
to discontinuation of treatment for intolerance to the drug,
adverse effects, or death was better for the placebo group
[26]. Some of the most important adverse events caused
by atypical antipsychotics are drowsiness, extrapyramidal
symptoms, and,more importantly, cerebrovascular accidents:
according to the placebo-controlled trials, for Risperidone
this possibility is 3-fold higher than placebo [21]. Another
important matter to be dealt with is the cognitive decline: the
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Figure 1: PubMed search on essential oils. An exponential growth
of scientific production about essential oils is displayed in the figure
from the 80s to 2016.
use of atypical antipsychotic agents over 12weeks is associated
with an accelerated cognitive decline assessed by MMSE
[24]. The FDA analyzed results of placebo-controlled trials
and outlined a 1,6-1,7-fold increased mortality in patients
subjected to atypical antipsychotics rather than placebo over
12 weeks [21, 27]. Moreover, the mortality at 12 months
was evaluated in a randomized placebo-controlled, parallel,
two-group treatment discontinuation trial [28]: the results
highlighted increased mortality both within the 12 months’
trial duration and during the 54 months of follow-up, thus
outlining the persistence of the risk of mortality increase
with the long-term treatment with antipsychotic drugs. By
contrast, another study to assess the antipsychotic-associated
long-term mortality was conducted throughout a 75-month
follow-up period in 4Norwegian counties, but it did not show
an increased mortality [29].
4. Complementary Approach through
Aromatherapy: Clinical Evidence and
Possible Pharmacological Mechanisms
Since the atypical antipsychotics should be used only in short-
term treatment and not over 12 weeks, there has been growing
interest in the use of aromatherapy for BPSDs handling
over the last years. Aromatherapy is a specialized segment
of phytotherapy that uses essential oils, extracted from the
different organs of aromatic plants, more often administered
via inhalation or topical application and massage for several,
minor, clinical uses [30]. A PubMed search, conducted using
“Essential oils” as key word, provided the graph shown in
Figure 1.
The remarkable increase of the scientific production
dealing with essential oils, occurring from the 80s to 2016,
accounts for the intensity of the phenomenon “aromather-
apy.” Indeed, during the second half of the past century, since
the first article published by Wood HC and Reichut ET in
1880 on the prestigious Journal of Physiology and entitled
“Note on the Action upon the Circulation of Certain Volatile
Oils,” the interest in aromatherapy for the treatment of
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several disorders such as anxiety,mood disorders, and certain
forms of pain registered a great growth [30]. Furthermore,
aromatherapy has provided the best evidence, together with
psychological treatment, for the management of agitation
in dementia [21]. In particular, the essential oils of two
species of Lamiaceae family, Melissa officinalis L. (lemon
balm) and Lavandula officinalis L. (lavender), are the most
used aromatherapeutic treatments for BPSDs in dementia
[31–33]. Melissa officinalis L. (Lemon balm) belongs to the
Lamiaceae family and is a traditional medicinal plant native
of East Mediterranean region and West Asia and widespread
in Teheran, where it is named Badranjbooye [34].
A placebo-controlled trial, conducted on patients affected
by severe dementia guests of care facilities in theUK, reported
the effect of Melissa officinalis (M. officinalis) essential oil,
applied as massage twice a day for 4 weeks, on agita-
tion measured by the Cohen-Mansfield agitation inventory
(CMAI) [31]: seventy-one out of the seventy-two participants
completed the trial and results demonstrated an improve-
ment of agitation without the occurrence of significant side
effects. The efficacy of lemon balm hydroalcoholic extracts
rather than the essential oil is also well documented. In a
study (a parallel group, double-blind, randomized, placebo-
controlled trial), involving aged patients (from 65 to 80 years
of age) suffering from mild-moderate AD, 60 drops/day of
lemon balm extract were administered. Lemon balm exerted
positive effects both on cognition, as measured through the
11-item cognitive subscale of the Alzheimer’s Disease Assess-
ment Scale (ADAS-cog) and the CDR-SB, and on agitation as
side effect at 4 months [35]. The effectiveness ofM. officinalis
in AD could be explained by some cholinergic activities that
have been detected in its extracts; this feature is shared also by
Salvia officinalis (sage) andGinkgo biloba [36, 37]. In a further
study [38], the crude lemon balm hydroalcoholic extract has
shown anticholinesterase activity. After fractionation, most
of its fractions resulted in being more active than the whole
extract. The constituents of the most active fractions are
represented by cis- and trans-rosmarinic acid isomers and a
rosmarinic acid derivative [38]. The high anticholinesterase
activity and free radical scavenger properties of rosmarinic
acid have been previously investigated by other authors
[39]. Moreover, it is reported that a similar extract of M.
officinalis contains compounds with acetylcholine receptor
affinities being higher for the nicotinic subtype of receptors
[40]. Therefore, the effects of M. officinalis could be due
to the content of rosmarinic acid mainly [41–43] and also
to the monoterpenoid constituents of the essential oil [41,
43]. Because of this hypothesis, a two-phase study was per-
formed using lemon balm dried leaves [43]. Preliminarily, the
inhibition of acetylcholinesterase (AChE) and nicotinic and
muscarinic receptor-binding properties were evaluated for
eight samples of dried leaves in human postmortem occipital
cortex tissue. Subsequently, the sample ofM. officinaliswhich
resulted to have the highest cholinergic activity was adminis-
tered to healthy young volunteers and the effects on cognition
and mood were examined in a multiple-dose, multiple time-
point, double-blind, placebo-controlled, balanced crossover
study [43]. Twenty healthy young participants received single
doses of 600, 1000, and 1600mg of encapsulated dried leaf,
or a matching placebo, at 7-day intervals. Cognitive perfor-
mance andmoodwere assessed before dose and at 1, 3, and 6 h
after dose, using the Cognitive Drug Research computerized
assessment battery and the Bond–Lader visual analog scales,
respectively. The obtained data supported the cholinergic
receptor-binding properties ofM. officinalis and the fact that
it acts onmood and cognition in a dose- and time-dependent
manner [43]. It is noteworthy that M. officinalis has shown
some effects also on nociceptive behaviour in animal pain
models and this could contribute to its effectiveness in the
reduction of agitation. In fact, the mechanisms involved
in the antinociceptive effects of a hydroalcoholic extract
of M. officinalis and of rosmarinic acid have been recently
investigated in mice [44]. In the formalin test, the extract
provided a significant inhibition of both phases and inhibited
in a dose-dependent manner the glutamate-induced pain.
The antinociceptive effect elicited by this extract in the
glutamate test was significantly attenuated by intraperitoneal
(i.p.) treatment of mice with atropine, mecamylamine, or L-
arginine but not with naloxone or D-arginine [44], thus sup-
porting the involvement of the cholinergic system and of the
L-arginine-nitric oxide pathway. In addition, the rosmarinic
acid contained in this extract appeared to contribute to the
antinociceptive features of M. officinalis extract [44]. Table 1
summarizes the main studies supporting the use of Melissa
officinalis in aromatherapy.
Lavender belongs to the family Labiatae (Lamiaceae).
Lavender essential oil is obtained by distillation of diverse
members of the genus Lavandula and it has been used for
centuries. Some of the enumerated most commonly used
species are L. officinalis (syn. L. angustifolia), L. latifolia, and
L. stoechas. L. angustifolia has been used for centuries in folk
medicine to treat anxiety and agitation: this is the reason
of the growing investigation of lavender aromatherapy for
the control of BPSDs. Lavender essential oil is composed of
over 100 constituents, among which the principal are linalool
(51%), linalyl acetate (35%), 𝛼-pinene, limonene, 1,8-cineole,
cis- and trans-ocimene, 3-octanone, camphor, caryophyl-
lene, terpinen-4-olandlavendulyl acetate, and cineole [45].
According to the existing literature, lavender essential oil is
able to inhibit glutamate and GABA receptor binding [46–
48] and to improve behavioural conflict between mice [48,
49]. Furthermore, lavender has been shown to lower plasma
cortisol levels [48, 50, 51] and reduce the need for analgesia
during the postoperative period in humans [48, 52]; a possible
action of lavender essential oil on tryptophan has also been
hypothesized [53, 54]. Lavender oil revealed also an interest-
ing analgesic activity relevant after inhalationmainly, at doses
devoid of sedative side effects [55]. In the hot plate test the oil
inhalation induced an analgesic activity which was inhibited
by naloxone, atropine, and mecamylamine before treatment,
thus supporting the involvement of both opioidergic and
cholinergic pathways [55]. A placebo-controlled trial includ-
ing 15 demented patients affected by agitation, according to
the PittsburghAgitation Scale (PAS), reported some effective-
ness of 2% lavender oil aromatherapy stream [32].The efficacy
of aromatherapy could be partly due to the terpenes content
of the used essential oils, since thesemolecules undergo quick
lung absorption and are able to cross the blood-brain barrier
Evidence-Based Complementary and Alternative Medicine 5
Table 1: Main studies supporting the use ofMelissa officinalis in aromatherapy.
Study Main characteristics
Ballard et al., 2002.
Placebo-controlled trial, conducted on seventy-two demented resident in care facilities in the
UK (seventy-one out of whom completed the trial), demonstrating thatM. officinalis essential
oil, applied as massage twice a day for 4 weeks, produced an improvement of agitation
(according to the CMAI), without the occurrence of significant side effects.
Akhondzadeh et al., 2003.
Parallel group, double-blind, randomized, placebo-controlled trial, involving aged patients
(from 65 to 80 years of age) suffering from mild-moderate AD, who were given 60 drops/day of
lemon balm extract. Lemon balm exerted positive effects both on cognition (according to the
ADAS-cog and the CDR-SB) and on agitation as side effect at 4 months.
Dastmalchi et al., 2009.
Fractionation of the crude lemon balm hydroalcoholic extract, demonstrating
anticholinesterase activity of most of the fractions, that resulted in being more active than the
whole extract. The constituents of the most active fractions are cis- and trans-rosmarinic acid
isomers and a rosmarinic acid derivative.
Kennedy et al., 2003.
Two-phase study: preliminary evaluation of the AChE inhibition and of nicotinic and
muscarinic receptor-binding properties for eight samples of lemon balm dried leaves in human
postmortem occipital cortex tissue and subsequent administration to 20 healthy young
participants of the sample that resulted to have the highest cholinergic activity. The effects on
cognition and mood were examined in a multiple-dose, multiple time-point, double-blind,
placebo-controlled, balanced crossover study. The obtained data supported the cholinergic
receptor-binding properties ofM. officinalis and the fact that it acts on mood and cognition in
a dose- and time-dependent manner.
Guginski et al., 2009.
Study performed using the formalin test in mice, in which theM. officinalis extract provided a
significant inhibition of both phases and inhibited in a dose-dependent manner the
glutamate-induced pain. The antinociceptive effect elicited by this extract in the glutamate test
was significantly attenuated by i.p. administered atropine, mecamylamine, or L-arginine but
not naloxone or D-arginine, thus supporting the involvement of the cholinergic system and of
the L-arginine-nitric oxide pathway. The rosmarinic acid contained in this extract appeared to
contribute to its antinociceptive features.
Table 2: Studies supporting the use of Lavandula officinalis in aromatherapy.
Study Main characteristics
Barocelli et al., 2004.
In the hot plate test the lavender oil inhalation induced analgesic activity, which was inhibited
by naloxone, atropine, and mecamylamine before treatment, thus supporting the involvement
of both opioidergic and cholinergic pathways.
Holmes et al., 2002. A placebo-controlled trial including 15 demented patients affected with agitation, as assessedby the PAS, which reported some effectiveness of 2% lavender oil aromatherapy stream.
Lin et al., 2007.
A cross-over randomized trial, conducted on 70 Chinese aged demented patients, which
suggested the efficacy of lavender administered by inhalatory route as adjunctive therapy for
the management of agitation.
Jimbo et al., 2009.
A group of 28 demented old patients, 17 of whom suffering from AD, was exposed to the aroma
of 0.04mL lemon and 0.08mL rosemary essential oil in the morning and to the aroma of
0.08mL lavender and 0.04mL orange essential oils in the evening, in order to improve
concentration and memory in the morning and to make the patients quiet in the evening. The
results obtained so far support the clinical use of aromatherapy in AD patients, also when
performed using more than one single essential oil.
[33]. A crossover randomized trial conducted on seventy
Chinese aged demented patients suggested the efficacy of
lavender administered by inhalatory route as an adjunctive
therapy for the management of agitation [56]. Moreover, the
effect of aromatherapy performed usingmore than one single
essential oil on dementia and AD was tested. A group of
28 demented old patients, 17 of whom suffering from AD,
was exposed to the aroma of 0.04mL lemon and 0.08mL
rosemary essential oil in the morning and to the aroma of
0.08mL lavender and 0.04mL orange essential oils in the
evening [57]. The rationale underneath this scheme relies on
the possibility that the mixed lemon and rosemary aromas
activate the sympathetic nervous system in order to improve
concentration and memory in the morning and the mixed
lavender and orange aromas activate the parasympathetic
nervous system, thusmaking the patients quiet in the evening
[57]. The results obtained so far support the clinical use of
aromatherapy in AD patients [57]. Table 2 summarizes the
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main studies supporting the use of Lavandula officinalis in
aromatherapy.
5. Conclusions and Future Perspectives
Dementia, of which AD represents the most prevalent eti-
ological factor, is a very complex social problem and it has
an even more remarkable burden in a future view, since
it is expected to affect more than 115 million people all
over the world by 2050 [58]. Apart from the urgent need
of disease-modifying drugs able to delay the progression
of the neurocognitive decline, another important aspect to
deal with is the management of aggression, agitation, and
psychotic symptoms, clustered under the acronym BPSDs,
which contribute to reduce the QoL and, in particular, the
health-related quality of life (HRQL) of patients suffering
from dementia. The pharmacological treatment of BPSDs
is represented by the atypical antipsychotics (Risperidone,
Olanzapine, Aripiprazole, and Quetiapine), among which
Risperidone is the safest drug for short-term therapy, with
necessary review of the treatment [15]. The employed treat-
ments, especially for BPSDs, affect the HRQL; the influence
of person-centred care (PCC), antipsychotic review, social
interaction, and exercise interventions on HRQL was studied
in the Improving Wellbeing and Health for People with
Dementia (WHELD) factorial cluster RCT in nursing home
residents [59]. The obtained results support the importance
of an adequate review of the antipsychotics use and of the
use of evidence-based nonpharmacological approaches as
combination therapy [59]. The atypical antipsychotic agents
for the management of BPSDs in patients suffering from
dementia should be used in the short term (6–12 weeks),
since they result in being safer and effective in this treatment
option (although almost exclusively on aggression rather than
on agitation), under rigorous review and in combination
with nonpharmacological interventions. Among the alter-
native treatments, aromatherapy has provided substantial
evidence for agitation handling in AD [21]. The mechanism
of action of constituents of aromatic plants has yet to be
discovered. Detailed information on psychological effects
of aromatic plants, their essential oils, and hydroalcoholic
extracts has been reported. The aromatic molecules bind
to olfactory epithelium acceptors that are specific for each
different smell. The olfactory nerve system is responsible for
the transmission of this stimulus to hippocampus, limbic
system, and amygdala and then to the hypothalamus with
consequent release of neuromediators [57]. The involvement
of hippocampus and amygdala in the cognitive impairment
characterizing dementia and the presence of neurofibrillary
tangles (NFTs) in the entorhinal cortex, already in the early
stages of AD [57, 60, 61], suggest an interesting link between
olfaction and AD, furtherly confirmed by the dysfunctional
olfaction by which demented patients are often affected [57].
It has been hypothesized that aromatherapy may promote
neurogenesis in dentate gyrus of hippocampus [57, 62].
Accordingly, systemic absorption (following direct inhalation
or inhalation after topical application) and distribution of
pharmacologically active components of the phytocomplex
are needed for aromatherapy to control BPSDs, and this may
minimize the role of the psychological action [30]. The most
used aromatherapeutic treatments for BPSDs in dementia are
represented by Melissa officinalis and Lavandula officinalis
[31–33]. Both of them have been used in traditional medicine
for centuries: for example, the documented historical uses
of M. officinalis date back to the “Materia Medica” in
approximately 50–80 BC [43]. In addition, essential oils from
both plants are included in the European Pharmacopoeia.
Another fundamental facet is the increase of pain states in
demented patients that are particularly related to agitation
and aggression [16]. There is promising evidence for the
effectiveness of aromatherapy for managing chronic pain:
it was demonstrated that the intraplantar administration
of Bergamot Essential Oil (BEO), a citrus fruit belonging
to the Rutaceae family, significantly attenuates capsaicin-
induced nociceptive behaviour [63] and both the first and
the second phase of formalin-induced nocifensive response,
thus confirming the previous observation that BEO reduces
mechanical allodynia in neuropathic pain models [64–66].
Therefore, more rigorous RCTs assessing the effectiveness of
aromatherapy on BPSDs, with recruitment of larger samples
of patients and longer duration, are needed [21]. Additional
basic research effort is necessary to understand the pharma-
cological mechanisms underlying aromatherapy. Finally, it is
fundamental to carry out pharmacovigilance for ensuring a
correct and safe application of aromatherapy.
Conflicts of Interest
The authors declare that there are no conflicts of interest
regarding the publication of this paper.
References
[1] A. Alzheimer, R. A. Stelzmann, H. N. Schnitzlein, and F. R.
Murtagh, “An English translation of Alzheimer’s 1907 paper,
‘Uber eine eigenartige Erkankung der Hirnrinde’,” Clinical
Anatomy, vol. 8, no. 6, pp. 429–431, 1995.
[2] C. Ballard,M. Orrell, S. Y. Zhong et al., “Impact of antipsychotic
review and nonpharmacological interventionon antipsychotic
use, neuropsychiatric symptoms, and mortality in people
with dementia living in nursing homes: a factorial cluster-
randomized controlled trial by the well-being and health for
people with dementia (WHELD) program,” American Journal
of Psychiatry, vol. 173, no. 3, pp. 252–262, 2016.
[3] S. H. Barage and K. D. Sonawane, “Amyloid cascade hypothesis:
pathogenesis and therapeutic strategies in Alzheimer’s disease,”
Neuropeptides, vol. 52, pp. 1–18, 2015.
[4] American Psychiatric Association, Diagnostic and Statistical
Manual of Mental Disorders, Third Edition-Revised (DSM-III-
R), American Psychiatric Association, Washington, DC, USA,
1987.
[5] American Psychiatric Association, Diagnostic and Statistical
Manual of Mental Disorders, (DSM-IV), American Psychiatric
Association, Washington, DC, USA, 4th edition, 1994.
[6] C. G. Ballard, S. Gauthier, J. L. Cummings et al., “Management
of agitation and aggression associated with Alzheimer disease,”
Nature Reviews Neurology, vol. 5, no. 5, pp. 245–255, 2009.
[7] W. Achterberg, M. J. Pieper, A. H. van Dalen-Kok et al., “Pain
management in patients with dementia,” Clinical Interventions
in Aging, vol. 8, pp. 1471–1482, 2013.
Evidence-Based Complementary and Alternative Medicine 7
[8] J. A. Hardy andG. A. Higgins, “Alzheimer’s disease: the amyloid
cascade hypothesis,” Science, vol. 256, no. 5054, pp. 184–185,
1992.
[9] J. L. Cummings, T.Morstorf, andK. Zhong, “Alzheimer’s disease
drug-development pipeline: few candidates, frequent failures,”
Alzheimer’s Research andTherapy, vol. 6, no. 4, article 37, 2014.
[10] R. S. Doody, R. G. Thomas, M. Farlow et al., “Phase 3 trials
of solanezumab for mild-to-moderate Alzheimer’s disease,”The
New England Journal of Medicine, vol. 370, no. 4, pp. 311–321,
2014.
[11] S. Salloway, R. Sperling, N. C. Fox et al., “Two phase 3 trials of
Bapineuzumab in mild-to-moderate Alzheimer’s disease,” The
New England Journal of Medicine, vol. 370, no. 4, pp. 322–333,
2014.
[12] J. Sevigny, P. Chiao, T. Bussie`re et al., “The antibody adu-
canumab reduces A𝛽 plaques in Alzheimer’s disease,” Nature,
vol. 537, no. 7618, pp. 50–56, 2016.
[13] A. Corbett, K. Nunez, and A. Thomas, “Coping with dementia
in care homes,”Maturitas, vol. 76, no. 1, pp. 3–4, 2013.
[14] M. Margallo-Lana, A. Swann, J. O’Brien et al., “Prevalence
and pharmacological management of behavioural and psycho-
logical symptoms amongst dementia sufferers living in care
environments,” International Journal of Geriatric Psychiatry, vol.
16, no. 1, pp. 39–44, 2001.
[15] C. Ballard and A. Corbett, “Agitation and aggression in people
withAlzheimer’s disease,”CurrentOpinion in Psychiatry, vol. 26,
no. 3, pp. 252–259, 2013.
[16] A. Corbett, B. Husebo, M. Malcangio et al., “Assessment and
treatment of pain in people with dementia,” Nature Reviews
Neurology, vol. 8, no. 5, pp. 264–274, 2012.
[17] C. Zarow, S. A. Lyness, J. A. Mortimer, and H. C. Chui, “Neu-
ronal loss is greater in the locus coeruleus than nucleus basalis
and substantia nigra in Alzheimer and Parkinson diseases,”
Archives of Neurology, vol. 60, no. 3, pp. 337–341, 2003.
[18] J. Parvizi, G. W. Van Hoesen, and A. Damasio, “Selective
pathological changes of the periaqueductal gray matter in
Alzheimer’s disease,” Annals of Neurology, vol. 48, no. 3, pp.
344–353, 2000.
[19] B. S. Husebo, C. Ballard, R. Sandvik, O. B. Nilsen, and D.
Aarsland, “Efficacy of treating pain to reduce behavioural
disturbances in residents of nursing homes with dementia:
cluster randomised clinical trial,”BMJ, vol. 343, no. 7816, Article
ID d4065, 2011.
[20] E. Lonergan, J. Luxenberg, and J. Colford, “Haloperidol for
agitation in dementia,” The Cochrane Database of Systematic
Reviews, no. 2, Article ID CD002852, 2002.
[21] C. G. Ballard, S. Gauthier, J. L. Cummings et al., “Management
of agitation and aggression associated with alzheimer disease,”
Nature Reviews Neurology, vol. 5, no. 5, pp. 245–255, 2009.
[22] J. G. Reilly, S. A. Ayis, I. N. Ferrier, S. J. Jones, and S. H. L.
Thomas, “QTc-interval abnormalities and psychotropic drug
therapy in psychiatric patients,” The Lancet, vol. 355, no. 9209,
pp. 1048–1052, 2000.
[23] C. Ballard and R. Howard, “Neuroleptic drugs in dementia:
benefits and harm,” Nature Reviews Neuroscience, vol. 7, no. 6,
pp. 492–500, 2006.
[24] L. S. Schneider, K. Dagerman, and P. S. Insel, “Efficacy and
adverse effects of atypical antipsychotics for dementia: meta-
analysis of randomized, placebo-controlled trials,” The Amer-
ican Journal of Geriatric Psychiatry, vol. 14, no. 3, pp. 191–210,
2006.
[25] C. Ballard, M. Margallo-Lana, E. Juszczak et al., “Quetiapine
and rivastigmine and cognitive decline in Alzheimer’s disease:
randomised double blind placebo controlled trial,” British
Medical Journal, vol. 330, no. 7496, pp. 874–877, 2005.
[26] L. S. Schneider, P. N. Tariot, K. S. Dagerman et al., “Effectiveness
of atypical antipsychotic drugs in patients with Alzheimer’s
disease,” The New England Journal of Medicine, vol. 355, no. 15,
pp. 1525–1538, 2006.
[27] FDA Public Health Advisory, “Deaths with antipsychotics in
elderly patients with behavioral disturbances,” 2005, https://
www.fda.gov/Drugs/DrugSafety/ucm053171.htm.
[28] C. Ballard, M. L. Hanney, M. Theodoulou et al., “The dementia
antipsychotic withdrawal trial (DART-AD): long-term follow-
up of a randomised placebo-controlled trial,” The Lancet Neu-
rology, vol. 8, no. 2, pp. 151–157, 2009.
[29] G. Selbæk, D. Aarsland, C. Ballard et al., “Antipsychotic drug
use is not associated with long-term mortality risk in Norwe-
gian nursing home patients,” Journal of the American Medical
Directors Association, vol. 17, no. 5, pp. 464.e1–464.e7, 2016.
[30] G. Bagetta, M. Cosentino, and T. Sakurada, Eds., Preface in
Aromatherapy: Basic Mechanisms and Evidence Based Clinical
Use, Oxfordshire, UK, Taylor & Francis, 2016.
[31] C. G. Ballard, J. T. O’Brien, K. Reichelt, and E. K. Perry,
“Aromatherapy as a safe and effective treatment for the man-
agement of agitation in severe dementia: the results of a double-
blind, placebo-controlled trial with Melissa,” Journal of Clinical
Psychiatry, vol. 63, no. 7, pp. 553–558, 2002.
[32] C. Holmes, V. Hopkins, C. Hensford, V. MacLaughlin, D.
Wilkinson, and H. Rosenvinge, “Lavender oil as a treatment
for agitated behaviour in severe dementia: a placebo controlled
study,” International Journal of Geriatric Psychiatry, vol. 17, no.
4, pp. 305–308, 2002.
[33] A. Burns, J. Byrne, C. Ballard, and C. Holmes, “Sensory
stimulation in dementia,” British Medical Journal, vol. 325, no.
7376, pp. 1312–1313, 2002.
[34] A. Zarei, S. Changizi Ashtiyani, S. Taheri, and F. Rasekh,
“Comparison between effects of different doses of Melissa
officinalis and atorvastatin on the activity of liver enzymes in
hypercholesterolemia rats,” Avicenna Journal of Phytomedicine,
vol. 4, no. 1, pp. 15–23, 2014.
[35] S. Akhondzadeh, M. Noroozian, M. Mohammadi, S. Ohadinia,
A. H. Jamshidi, and M. Khani, “Melissa officinalis extract in
the treatment of patients with mild to moderate Alzheimer’s
disease: a double blind, randomised, placebo controlled trial,”
Journal of Neurology, Neurosurgery, and Psychiatry, vol. 74, no.
7, pp. 863–866, 2003.
[36] E. K. Perry, A. T. Pickering,W.W.Wang, P. Houghton, andN. S.
L. Perry, “Medicinal plants and Alzheimer’s disease: integrating
ethnobotanical and contemporary scientific evidence,” Journal
of Alternative and Complementary Medicine, vol. 4, no. 4, pp.
419–428, 1998.
[37] E. K. Perry, A. T. Pickering, W. W. Wang, P. J. Houghton,
and N. S. L. Perry, “Medicinal plants and Alzheimer’s disease:
from ethnobotany to phytotherapy,” Journal of Pharmacy and
Pharmacology, vol. 51, no. 5, pp. 527–534, 1999.
[38] K. Dastmalchi, V. Ollilainen, P. Lackman et al., “Acetyl-
cholinesterase inhibitory guided fractionation of Melissa offic-
inalis L.,” Bioorganic and Medicinal Chemistry, vol. 17, no. 2, pp.
867–871, 2009.
[39] M. Petersen and M. S. J. Simmonds, “Rosmarinic acid,” Phyto-
chemistry, vol. 62, no. 2, pp. 121–125, 2003.
8 Evidence-Based Complementary and Alternative Medicine
[40] G. Wake, J. Court, A. Pickering, R. Lewis, R. Wilkins, and
E. Perry, “CNS acetylcholine receptor activity in European
medicinal plants traditionally used to improve failing memory,”
Journal of Ethnopharmacology, vol. 69, no. 2, pp. 105–114, 2000.
[41] A. P. Carnat, A. Carnat, D. Fraisse, and J. L. Lamaison, “The
aromatic andpolyphenolic composition of lemonbalm (Melissa
officinalis L. subsp. officinalis) tea,” Pharmaceutica Acta Helve-
tiae, vol. 72, no. 5, pp. 301–305, 1998.
[42] J. Hohmann, I. Zupko´, D. Re´dei et al., “Protective effects of
the aerial parts of Salvia officinalis, Melissa officinalis and
Lavandula angustifolia and their constituents against enzyme-
dependent and enzyme-independent lipid peroxidation,”Planta
Medica, vol. 65, no. 6, pp. 576–578, 1999.
[43] D. O. Kennedy, G. Wake, S. Savelev et al., “Modulation of mood
and cognitive performance following acute administration of
single doses of Melissa officinalis (Lemon balm) with human
CNS nicotinic and muscarinic receptor-binding properties,”
Neuropsychopharmacology, vol. 28, no. 10, pp. 1871–1881, 2003.
[44] G. Guginski, A. P. Luiz, M. D. Silva et al., “Mechanisms involved
in the antinociception caused by ethanolic extract obtained
from the leaves of Melissa officinalis (lemon balm) in mice,”
Pharmacology Biochemistry and Behavior, vol. 93, no. 1, pp. 10–
16, 2009.
[45] H. M. A. Cavanagh and J. M. Wilkinson, “Biological activities
of lavender essential oil,” Phytotherapy Research, vol. 16, no. 4,
pp. 301–308, 2002.
[46] E. Elisabetsky, J. Marschner, and D. Onofre Souza, “Effects of
linalool on glutamatergic system in the rat cerebral cortex,”
Neurochemical Research, vol. 20, no. 4, pp. 461–465, 1995.
[47] L. Huang, S. Abuhamdah, M.-J. R. Howes et al., “Pharmacolog-
ical profile of essential oils derived from Lavandula angustifolia
and Melissa officinalis with anti-agitation properties: focus on
ligand-gated channels,” Journal of Pharmacy and Pharmacology,
vol. 60, no. 11, pp. 1515–1522, 2008.
[48] D.W.O’Connor, B. Eppingstall, J. Taffe, and E. S. VanDer Ploeg,
“A randomized, controlled cross-over trial of dermally-applied
lavender (Lavandula angustifolia) oil as a treatment of agitated
behaviour in dementia,” BMC Complementary and Alternative
Medicine, vol. 13, article 315, 2013.
[49] T. Umezu, “Behavioral effects of plant-derived essential oils
in the geller type conflict test in mice,” Japanese Journal of
Pharmacology, vol. 83, no. 2, pp. 150–153, 2000.
[50] Y. Shiina, N. Funabashi, K. Lee et al., “Relaxation effects of
lavender aromatherapy improve coronary flow velocity reserve
in healthy men evaluated by transthoracic Doppler echocardio-
graphy,” International Journal of Cardiology, vol. 129, no. 2, pp.
193–197, 2008.
[51] T. Field, T. Field, C. Cullen et al., “Lavender bath oil reduces
stress and crying and enhances sleep in very young infants,”
Early Human Development, vol. 84, no. 6, pp. 399–401, 2008.
[52] J. T. Kim, C. J. Ren, G. A. Fielding et al., “Treatment with
lavender aromatherapy in the post-anesthesia care unit reduces
opioid requirements of morbidly obese patients undergoing
laparoscopic adjustable gastric banding,” Obesity Surgery, vol.
17, no. 7, pp. 920–925, 2007.
[53] C. A. Zeilmann, E. J. Dole, B. J. Skipper, M. McCabe, T. Low
Dog, and R. L. Rhyne, “Use of herbal medicine by elderly
Hispanic and non-Hispanic white patients,” Pharmacotherapy,
vol. 23, no. 4, pp. 526–532, 2003.
[54] C.-Y. Fu, W. Moyle, and M. Cooke, “A randomised controlled
trial of the use of aromatherapy and hand massage to reduce
disruptive behaviour in people with dementia,” BMC Comple-
mentary and Alternative Medicine, vol. 13, article 165, 2013.
[55] E. Barocelli, F. Calcina, M. Chiavarini et al., “Antinociceptive
and gastroprotective effects of inhaled and orally administered
Lavandula hybrida Reverchon ‘grosso’ essential oil,” Life Sciences,
vol. 76, no. 2, pp. 213–223, 2004.
[56] P. W.-K. Lin, W.-C. Chan, B. F.-L. Ng, and L. C.-W. Lam,
“Efficacy of aromatherapy (Lavandula angustifolia) as an inter-
vention for agitated behaviours in Chinese older persons with
dementia: a cross-over randomized trial,” International Journal
of Geriatric Psychiatry, vol. 22, no. 5, pp. 405–410, 2007.
[57] D. Jimbo, Y. Kimura, M. Taniguchi, M. Inoue, and K. Urakami,
“Effect of aromatherapy on patients with Alzheimer’s disease,”
Psychogeriatrics, vol. 9, no. 4, pp. 173–179, 2009.
[58] World Health Organization and Alzheimer’s Disease Inter-
national, Dementia: A Public Health Priority, World Health
Organization, Geneva, Switzerland, 2012.
[59] C. Ballard, M. Orrell, Y. Sun et al., “Impact of antipsychotic
review and nonpharmacological intervention on antipsychotic
use, neuropsychiatric symptoms, and mortality in people
with dementia living in nursing homes: a factorial cluster-
randomized controlled trial by the Well-Being and Health for
People With Dementia (WHELD) program,” The American
Journal of Psychiatry, vol. 173, no. 3, pp. 252–262, 2016.
[60] H. Braak and E. Braak, “Neuropathological stageing of
Alzheimer-related changes,” Acta Neuropathologica, vol. 82, no.
4, pp. 239–259, 1991.
[61] G. Gold, C. Bouras, E. Ko¨vari et al., “Clinical validity of Braak
neuropathological staging in the oldest-old,” Acta Neuropatho-
logica, vol. 99, no. 5, pp. 579–584, 2000.
[62] P. S. Eriksson, E. Perfilieva, T. Bjo¨rk-Eriksson et al., “Neurogen-
esis in the adult human hippocampus,” Nature Medicine, vol. 4,
no. 11, pp. 1313–1317, 1998.
[63] T. Sakurada, H. Kuwahata, S. Katsuyama et al., “Chapter 18
intraplantar injection of bergamot essential oil into the mouse
hindpaw. Effects on capsaicin-induced nociceptive behaviors,”
International Review of Neurobiology, vol. 85, pp. 237–248, 2009.
[64] G. Bagetta, L. A. Morrone, L. Rombola` et al., “Neuropharma-
cology of the essential oil of bergamot,” Fitoterapia, vol. 81, no.
6, pp. 453–461, 2010.
[65] H. Kuwahata, T. Komatsu, S. Katsuyama et al., “Peripherally
injected linalool and bergamot essential oil attenuate mechan-
ical allodynia via inhibiting spinal ERK phosphorylation,”
Pharmacology Biochemistry and Behavior, vol. 103, no. 4, pp.
735–741, 2013.
[66] S. Katsuyama, A. Otowa, S. Kamio et al., “Effect of plantar
subcutaneous administration of bergamot essential oil and
linalool on formalin-induced nociceptive behavior in mice,”
Biomedical Research, vol. 36, no. 1, pp. 47–54, 2015.
